Neoadjuvant Chemotherapy Plus Nivolumab with or Without Ipilimumab in Operable Non-Small Cell Lung Cancer: the Phase 2 Platform NEOSTAR Trial

Tina Cascone,Cheuk H. Leung,Annikka Weissferdt,Apar Pataer,Brett W. Carter,Myrna C. B. Godoy,Hope Feldman,William N. William Jr,Yuanxin Xi,Sreyashi Basu, Jing,Shalini S. Yadav,Frank R. Rojas Alvarez,Younghee Lee,Aditya K. Mishra,Lili Chen,Monika Pradhan,Haiping Guo,Ansam Sinjab,Nicolas Zhou,Marcelo V. Negrao,Xiuning Le,Carl M. Gay,Anne S. Tsao,Lauren Averett Byers,Mehmet Altan,Bonnie S. Glisson,Frank V. Fossella,Yasir Y. Elamin,George Blumenschein Jr,Jianjun Zhang,Ferdinandos Skoulidis,Jia Wu,Reza J. Mehran,David C. Rice,Garrett L. Walsh,Wayne L. Hofstetter,Ravi Rajaram,Mara B. Antonoff,Junya Fujimoto,Luisa M. Solis,Edwin R. Parra,Cara Haymaker,Ignacio I. Wistuba,Stephen G. Swisher,Ara A. Vaporciyan,Heather Y. Lin,Jing Wang,Don L. Gibbons,J. Jack Lee,Nadim J. Ajami,Jennifer A. Wargo,James P. Allison,Padmanee Sharma,Humam Kadara,John V. Heymach,Boris Sepesi

Nature Medicine（2023）

Cited 79|Views154

Key words

Non-small-cell lung cancer,Phase II trials,Translational immunology,Translational research,Tumour immunology,Biomedicine,general,Cancer Research,Metabolic Diseases,Infectious Diseases,Molecular Medicine,Neurosciences

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined